Oncology
2017/03/01CONFERENCE
BSH 2017
British Society for Haematology Annual Scientific Meeting 27-29 March 2017, Brighton
2016/02/03CONFERENCE
ESMO 2016
European Society for Medical Oncology - 18th World Congress on Gastrointestinal Cancer | 29 June - 2 July 2016 | Barcelona. http://worldgicancer.com/WCGI/WGIC2016/index.asp
2018/10/17MEDICAL UPDATE
WCLC 2018: Variety of approaches can work in oligometastatic disease
By Thomas R Collins / Interviewer Esther Drain Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on Lung Cancer.
2018/10/17MEDICAL UPDATE
WCLC 2018: Lung cancer stigma is detrimental to patient care
Interviewer Esther Drain Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients' care.
2018/10/17MEDICAL UPDATE
WCLC 2018: Importance of QOL outcome measures in clinical trials
Interviewer Esther Drain WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.
2018/10/17MEDICAL UPDATE
WCLC 2018: Accessibility & quality of life: a patient focus at WCLC
By Thomas R Collins / Interview by Esther Drain Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said here at the IASLC 19th World Conference on Lung Cancer.
2018/10/17MEDICAL UPDATE
WCLC 2018: PACIFIC: durvalumab results impressive, but not without questions
By Thomas R Collins / Interview by Esther Drain Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the latest results of the phase III PACIFIC trial presented here at the IASLC 19th World Conference on Lung Cancer.
2018/10/17MEDICAL UPDATE
WCLC 2018: Early ALTA-1L data encouraging for brigatinib
By Thomas R Collins / Interviews by Esther Drain The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with ALK-positive non-small cell lung cancer (NSCLC) who hadn’t yet received an ALK-inhibitor, researchers said here in the Plenary at the IASLC 19th World Congress on Lung Cancer.
